Bodovitz S, Klein WL (1996) Cholesterol modulates alpha-secretase cleavage of amyloid
precursor protein. J Biol Chem 271: 4436–4440
Braak H, Braak E, Ohm T, Bohl J (1989) Alzheimer's disease: mismatch between amyloid plaques and neuritic plaques. Neurosci Lett 103: 24–28
Ciruzzi M, Schargrodsky H, Rozlosnik J, Pramparo P, Delmonte H, Rudich V, Piskorz D,
Negri E, Soifer S, La Vecchia C (1997) Frequency of family history of acute myocardial infarction in patients with acute myocardial infarction. Argentine FRICAS
(Factores de Riesgo Coronario en America del Sur) Investigators. Am J Cardiol 80:
122–127
Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H,
Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T
(2001) Simvastatin strongly reduces levels of Alzheimer's disease -amyloid
peptides A 42 and A 40 in vitro and in vivo. Proc Natl Acad Sci USA 98: 5856–
5861
Grant WB (1997) Dietary links to Alzheimer's disease. Alz Dis Rev 2: 42–55
Howland DS, Trusko SP, Savage MJ, Reaume AG, Lang DM, Hirsch JD, Maeda N,
Siman R, Greenberg BD, Scott RW, Flood DG (1998) Modulation of secretedamyloid precursor protein and amyloid -peptide in brain by cholesterol. J Biol Chem
273: 16576–16582
Jarvik GP, Austin MA, Fabsitz RR, Auwerx J, Reed T, Christian JC, Deeb S (1994)
Genetic influences on age-related change in total cholesterol, low density lipoproteincholesterol, and triglyceride levels: longitudinal apolipoprotein E genotype effects.
Genet Epidemiol 11: 375–384
Jen CJ, Chan HP, Chen HI (2002) Chronic exercise improves endothelial calcium signaling and vasodilatation in hypercholesterolemic rabbit femoral artery. Arterioscler
Thromb Vasc Biol 22: 1219–1224
Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of
dementia. Lancet 356: 1627–1631
Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M,
Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L (1997) Amyloid
precursor protein processing and A 42 deposition in a transgenic mouse model of
Alzheimer disease. Proc Natl Acad Sci USA 94: 1550–1555
Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Iivonen
S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen H (2002) Apolipoprotein E ε4
allele, elevate midlife total cholesterol level, and high midlife systolic blood pressure
are independent risk factors for late-life Alzheimer disease. Ann Int Med 137: 149–
155
Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F (2001) Low cholesterol stimulates
the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc
Natl Acad Sci USA 98: 5815–5820
Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D, Roher
AE (1998) Elevated low-density lipoprotein in Alzheimer's disease correlates with
brain A 1–42 levels. Biochem Biophys Res Commun 252: 711–715
Kuo YM, Crawford F, Mullan M, Kokjohn TA, Emmerling MR, Weller RO, Roher AE
(2000a) Elevated A and apolipoprotein E in A PP transgenic mice and its relationship to amyloid accumulation in Alzheimer's disease. Mol Med 6: 430–439
Kuo YM, Kokjohn TA, Watson MD, Woods AS, Cotter RJ, Sue LI, Kalback WM,
Emmerling MR, Beach TG, Roher AE (2000b) Elevated A 42 in skeletal muscle of
Alzheimer disease patients suggests peripheral alterations of A PP metablism. Am J
Pathol 156: 797–805
Lue LF, Kuo YM, Roher AE, Brachoval L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE,
Rogers J (1999) Soluble amyloid peptide concentration as a predictor of synaptic
change in Alzheimer's disease. Am J Pathol 155: 853–862
Nezil FA, Bloom M (1992) Combined influence of cholesterol and synthetic amphiphillic
peptides upon bilayer thickness in model membranes. Biophys J 61: 1176–1183
